Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study.
CCC19
COVID-19
SARS-CoV-2
sarcoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
05 Sep 2022
05 Sep 2022
Historique:
received:
16
07
2022
revised:
26
08
2022
accepted:
29
08
2022
entrez:
9
9
2022
pubmed:
10
9
2022
medline:
10
9
2022
Statut:
epublish
Résumé
Patients with sarcoma often require individualized treatment strategies and are likely to receive aggressive immunosuppressive therapies, which may place them at higher risk for severe COVID-19. We aimed to describe demographics, risk factors, and outcomes for patients with sarcoma and COVID-19. We performed a retrospective cohort study of patients with sarcoma and COVID-19 reported to the COVID-19 and Cancer Consortium (CCC19) registry (NCT04354701) from 17 March 2020 to 30 September 2021. Demographics, sarcoma histologic type, treatments, and COVID-19 outcomes were analyzed. of 281 patients, 49% ( Patients with sarcoma have high rates of severe COVID-19 and those with bone sarcoma may have the greatest risk of death.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with sarcoma often require individualized treatment strategies and are likely to receive aggressive immunosuppressive therapies, which may place them at higher risk for severe COVID-19. We aimed to describe demographics, risk factors, and outcomes for patients with sarcoma and COVID-19.
METHODS
METHODS
We performed a retrospective cohort study of patients with sarcoma and COVID-19 reported to the COVID-19 and Cancer Consortium (CCC19) registry (NCT04354701) from 17 March 2020 to 30 September 2021. Demographics, sarcoma histologic type, treatments, and COVID-19 outcomes were analyzed.
RESULTS
RESULTS
of 281 patients, 49% (
CONCLUSIONS
CONCLUSIONS
Patients with sarcoma have high rates of severe COVID-19 and those with bone sarcoma may have the greatest risk of death.
Identifiants
pubmed: 36077869
pii: cancers14174334
doi: 10.3390/cancers14174334
pmc: PMC9454925
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA177558
Pays : United States
Organisme : NIH HHS
ID : UL1 TR000445
Pays : United States
Organisme : NIH HHS
ID : P30 CA068485
Pays : United States
Références
J Oncol Pract. 2016 Mar;12(3):208-16
pubmed: 26962160
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
Orphanet J Rare Dis. 2007 Jan 23;2:6
pubmed: 17244349
JCO Glob Oncol. 2020 Jun;6:799-808
pubmed: 32511066
Eur J Cancer. 2020 Nov;139:43-50
pubmed: 32971510
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
JAMA Netw Open. 2022 May 2;5(5):e2212686
pubmed: 35579900
Euro Surveill. 2021 Oct;26(41):
pubmed: 34651577
Cancer. 2008 Feb 15;112(4):909-18
pubmed: 18189295
JAMA Netw Open. 2021 Nov 1;4(11):e2134147
pubmed: 34762110
Semin Oncol. 1996 Jun;23(3 Suppl 6):22-6
pubmed: 8677444
Expert Rev Anticancer Ther. 2002 Apr;2(2):201-15
pubmed: 12113242
Int J Infect Dis. 2022 Jan;114:252-260
pubmed: 34800687
Cancer Cell. 2020 Dec 14;38(6):761-766
pubmed: 33176160
Cancer. 2014 Jun 15;120(12):1763-74
pubmed: 24648013
Cancer Invest. 2021 Apr;39(4):315-320
pubmed: 33720792
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Ann Oncol. 2021 Jun;32(6):787-800
pubmed: 33746047
J Int Med Res. 2022 Mar;50(3):3000605221086155
pubmed: 35313761
JCO Oncol Pract. 2021 Sep;17(9):e1318-e1326
pubmed: 34264741
Cancer Discov. 2020 Jul;10(7):935-941
pubmed: 32357994
JAMA. 2022 Aug 23;328(8):772-773
pubmed: 35925592
Semin Oncol. 1999 Feb;26(1):119-33
pubmed: 10073568
Infect Dis Poverty. 2021 Nov 14;10(1):132
pubmed: 34776011
Adv Surg. 2015;49:107-22
pubmed: 26299493
JAMA Netw Open. 2022 Mar 1;5(3):e224304
pubmed: 35344045